<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-152980" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Deucravacitinib</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kalola</surname>
            <given-names>Urvashi K.</given-names>
          </name>
          <aff>Shree Pramukhswami Medical College, Karamsad</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alberty</surname>
            <given-names>Anastasia</given-names>
          </name>
          <aff>Lake Erie College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sheehy</surname>
            <given-names>Conor</given-names>
          </name>
          <aff>University of Washington</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Urvashi Kalola declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anastasia Alberty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Conor Sheehy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-152980.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">
<bold>FDA-Approved Indications</bold>
</p>
        <p>Deucravacitinib is the first Janus kinase (Jak) inhibitor medication found to inhibit tyrosine kinase 2 (Tyk2) selectively.<xref ref-type="bibr" rid="article-152980.r1">[1]</xref><xref ref-type="bibr" rid="article-152980.r2">[2]</xref>&#x000a0;The U.S. Food and Drug Administration (FDA) approved deucravacitinib on September 9th, 2022,&#x000a0;as a treatment for adult patients with moderate-to-severe plaque psoriasis, provided these patients are candidates for systemic therapy or phototherapy.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref><xref ref-type="bibr" rid="article-152980.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Various&#x000a0;diseases&#x000a0;involve the overexpression of type I interferons (IFN-&#x003b1; and&#x000a0;&#x003b2;), including&#x000a0;systemic lupus erythematosus (SLE), systemic sclerosis, and Sj&#x000f6;gren syndrome. Patients with these conditions may benefit from deucravacitinib therapy.<xref ref-type="bibr" rid="article-152980.r5">[5]</xref>&#x000a0;Multiple studies have&#x000a0;demonstrated the beneficial effects of deucravacitinib therapy for patients with various autoimmune conditions&#x000a0;other than plaque psoriasis. Despite this demonstrated benefit, the FDA has not approved the administration of deucravacitinib for these patients. These off-label&#x000a0;uses&#x000a0;include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Generalized pustular psoriasis&#x000a0;<xref ref-type="bibr" rid="article-152980.r3">[3]</xref><xref ref-type="bibr" rid="article-152980.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Erythrodermic psoriasis&#x000a0;<xref ref-type="bibr" rid="article-152980.r3">[3]</xref><xref ref-type="bibr" rid="article-152980.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis&#x000a0;<xref ref-type="bibr" rid="article-152980.r6">[6]</xref><xref ref-type="bibr" rid="article-152980.r7">[7]</xref><xref ref-type="bibr" rid="article-152980.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Moderate-to-severe scalp psoriasis&#x000a0;<xref ref-type="bibr" rid="article-152980.r9">[9]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alopecia areata and alopecia universalis&#x000a0;<xref ref-type="bibr" rid="article-152980.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Nail psoriasis&#x000a0;<xref ref-type="bibr" rid="article-152980.r11">[11]</xref><xref ref-type="bibr" rid="article-152980.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Oral psoriasis&#x000a0;<xref ref-type="bibr" rid="article-152980.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Plaque psoriasis involving the palms and soles&#x000a0;<xref ref-type="bibr" rid="article-152980.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus <xref ref-type="bibr" rid="article-152980.r7">[7]</xref><xref ref-type="bibr" rid="article-152980.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Discoid lupus erythematosus&#x000a0;<xref ref-type="bibr" rid="article-152980.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Subacute cutaneous&#x000a0;lupus erythematosus&#x000a0;<xref ref-type="bibr" rid="article-152980.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Lupus nephritis</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease (ie, Crohn disease and ulcerative colitis)&#x000a0;<xref ref-type="bibr" rid="article-152980.r7">[7]</xref><xref ref-type="bibr" rid="article-152980.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis&#x000a0;<xref ref-type="bibr" rid="article-152980.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Erosive oral lichen planus&#x000a0;<xref ref-type="bibr" rid="article-152980.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis&#x000a0;<xref ref-type="bibr" rid="article-152980.r16">[16]</xref><xref ref-type="bibr" rid="article-152980.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Dermatomyositis&#x000a0;<xref ref-type="bibr" rid="article-152980.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Spondyloarthropathies (eg, ankylosing spondylitis)&#x000a0;<xref ref-type="bibr" rid="article-152980.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-152980.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tyrosine kinase 2 (Tyk2)&#x000a0;is&#x000a0;one of the Janus kinase (Jak) enzymes, which are intracellular tyrosine kinases&#x000a0;that&#x000a0;activate the Jak&#x02013;signal transducer and the transcription (Jak-STAT) pathway. The&#x000a0;remaining Janus kinase enzymes (ie, Jak1, Jak2, Jak3) stimulate a&#x000a0;broad range of immune and extra-immune pathways (eg, lipid metabolism). In contrast, Tyk2-mediated signaling is&#x000a0;involved&#x000a0;with relatively few immune pathways.</p>
        <p>Tyk2 promotes the signaling of inflammatory cytokines involved in innate (eg, type I interferons) and adaptive (eg, interleukins 12 and 23) immune responses. Interleukin 23 (IL-23) is associated with the pathogenesis of psoriasis and psoriatic arthritis.&#x000a0;This cytokine initiates and stimulates the proliferation of T<sub>H</sub>17 cells, which secrete inflammation mediators such as tumor necrosis factor-alpha (TNF-&#x003b1;) and IL-17. These signal molecules&#x000a0;stimulate epidermal cell&#x000a0;production and secretion of cytokines and chemokines that recruit and activate cells of the innate immune system. This upregulated T<sub>H</sub>17 cell activity&#x000a0;causes sustained inflammation in the skin and joints, as seen in psoriatic arthritis.</p>
        <p>The drug demonstrates a strong affinity for this domain, making it highly selective for Tyk2 compared to other tyrosine kinases.&#x000a0;During&#x000a0;in vitro studies, deucravacitinib manifested a 100- to 2000-fold selectivity&#x000a0;for Tyk2&#x000a0;compared to Jak1, 2, and 3. Additionally, deucravacitinib exhibited minimal or no binding of&#x000a0;Jak1, 2, and 3.</p>
        <p>Deucravacitinib binds allosterically to&#x000a0;the regulatory domain of Tyk2 (JH2, or pseudokinase), a region that is typically catalytically inactive.&#x000a0;The drug induces an inhibitory conformation change&#x000a0;involving the locking of Tyk2's JH2 (regulatory) domain with its JH1 (catalytic) domain.&#x000a0;Thus, deucravacitinib traps the Tyk2 protein in an inactive state.<xref ref-type="bibr" rid="article-152980.r19">[19]</xref><xref ref-type="bibr" rid="article-152980.r20">[20]</xref>&#x000a0;</p>
        <p>Inhibition of Tyk2 promotes downregulation of the IL-23 (T<sub>H</sub>17), type I interferon, IL-12, and keratinocyte activation pathways. However, the precise mechanism linking Tyk2 inhibition to the effective treatment of moderate-to-severe plaque psoriasis is unknown.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;In patients with psoriasis, deucravacitinib&#x000a0;reduces the expression of psoriasis-associated genes in a dose-dependent fashion. This includes reducing type I IFN pathway-regulated genes and the IL-23 pathway. Deucravacitinib&#x000a0;reduces&#x000a0;IL-17A levels by 47% to 50%, IL-19 by 72%, and &#x003b2;-defensin by 81% to 84% after once-daily&#x000a0;administration for 16 weeks. However, the&#x000a0;mechanism&#x000a0;linking&#x000a0;these reduced inflammation marker levels&#x000a0;to the clinical effects of deucravacitinib&#x000a0;has&#x000a0;not been established.</p>
        <p>Additionally,&#x000a0;the selectivity of deucravacitinib for Tyk2&#x000a0;reduces the risk of adverse reactions,&#x000a0;giving the drug a favorable safety profile.&#x000a0;When administered transdermally,&#x000a0;deucravacitinib also&#x000a0;demonstrates&#x000a0;significant antioxidative properties.<xref ref-type="bibr" rid="article-152980.r21">[21]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Following an oral dose of deucravacitinib, the Cmax and AUC increased proportionally, exhibiting linear pharmacokinetics. The absolute bioavailability of deucravacitinib was 99%, and the median Tmax was achieved in 2 to 3 hours.<xref ref-type="bibr" rid="article-152980.r22">[22]</xref>&#x000a0;The PK of deucravacitinib and its major active metabolite (BMT-153261) were almost comparable between healthy controls and&#x000a0;patients with psoriasis.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;A once-daily 6 mg dosing regimen resulted in a steady-state Cmax and AUC of deucravacitinib&#x000a0;of 45 ng/mL and 473 ng/mL, respectively. The same dose resulted in a&#x000a0;steady-state Cmax and AUC<sub>24</sub> of BMT-153261 of 5 ng/mL and 95 ng&#x000b7;hr/mL, respectively.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;No significant differences were&#x000a0;observed after a calorie-dense, high-fat meal&#x000a0;of 51 total kcal&#x000a0;with an approximate macronutrient distribution of 33% carbohydrates, 15% protein, and 52% fat.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;When administered with food, the Cmax and AUC of deucravacitinib&#x000a0;were reduced by approximately 24% and 11%, respectively, and the Tmax was prolonged by 1 hour. When administered with food, Cmax and AUC of BMT-153261&#x000a0;were reduced by approximately 23% and 10%, respectively, and the Tmax was&#x000a0;prolonged by 2 hours.</p>
        <p><bold>Distribution:</bold> At a steady state, the volume of distribution of deucravacitinib was 140 L. Eighty-two percent to 90% of deucravacitinib was protein-bound, and its blood-to-plasma concentration ratio was 1.26. Patient body weight, age, gender, race, and ethnicity did not have a clinically significant effect on systemic exposure to deucravacitinib.<xref ref-type="bibr" rid="article-152980.r23">[23]</xref></p>
        <p><bold>Metabolism:</bold> Deucravacitinib undergoes N-demethylation mediated by cytochrome P-450 (CYP) 1A2 to form the metabolite BMT-153261, which demonstrates comparable pharmacological activity to the parent drug. The circulating BMT-153261 accounts for approximately 20% of the systemic exposure of the total drug-related components. Deucravacitinib is also metabolized by CYP2B6, CYP2D6, carboxylesterase (CES) 2, and uridine glucuronyl transferase (UGT) 1A9.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref><xref ref-type="bibr" rid="article-152980.r20">[20]</xref></p>
        <p><bold>Elimination:</bold> The terminal half-life of deucravacitinib is 10 hours.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;The renal clearance of deucravacitinib ranges from 27 to 54 mL/min. After administration of a single&#x000a0;radiolabeled deucravacitinib dose, about 13% and 26% were excreted unchanged in urine and feces, respectively. Approximately 6% and 12% of this single dose were recovered as BMT-153261 in urine and feces, respectively.</p>
      </sec>
      <sec id="article-152980.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Deucravacitinib is available as a 6 mg oral tablet.</p>
        <p>Each tablet contains the active ingredient deucravacitinib and the following inactive excipients: croscarmellose sodium, anhydrous lactose, magnesium stearate, hypromellose acetate succinate, silicon dioxide, and microcrystalline cellulose. In addition, the Opadry II Pink&#x000a0;component of the coating contains the following inactive components: iron oxide yellow, iron oxide red, polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The recommended dose is one 6 mg tablet taken once daily regardless of food.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref><xref ref-type="bibr" rid="article-152980.r24">[24]</xref>&#x000a0;The patient should not chew, crush, or cut the tablets.</p>
        <p>
<bold>Storage and Handling:</bold>
</p>
        <p>Deucravacitinib tablets are stored at 68 to 77 &#x000b0;F (20 to 25 &#x000b0;C); temperature excursions are permitted between 59 and 86 &#x000b0;F (15 to 30 &#x000b0;C). Deucravacitinib is chemically a free base; its molecular formula is C20H19D3N8O3. The molecular weight of this compound is 425.47 g/mol. Deucravacitinib is a powder in physical form and appears white to yellow. The solubility of deucravacitinib depends on the pH of the solvent. The solubility increases with decreasing pH.&#x000a0;</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Kidney function can significantly&#x000a0;affect the Cmax of deucravacitinib. In&#x000a0;patients with mild renal dysfunction (GFR 60 to 90 mL/min/1.73 m<sup>2</sup>), the Cmax was 14% lower compared to patients with normal kidney function (GFR&#x000a0;&#x0003e;90 mL/min/1.73 m<sup>2</sup>). In patients with moderate renal impairment (GFR 30 to 60 mL/min/1.73 m<sup>2</sup>), the Cmax was 6% higher than patients with normal kidney function. There was no significant difference in Cmax in&#x000a0;patients&#x000a0;with severe renal failure (GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup>) or end-stage renal disease (ESRD) (GFR &#x0003c;15mL/min/1.73 m<sup>2</sup>)&#x000a0;on&#x000a0;dialysis compared to patients with normal kidney function. No significant&#x000a0;differences in the AUC of deucravacitinib were observed in&#x000a0;patients with mild renal failure. However, the AUC was higher by 39%, 28%, and 34% in&#x000a0;patients with moderate, severe, and end-stage kidney disease on dialysis, respectively. The Cmax of MBT-153261 was 11% and 8% lower in&#x000a0;patients with mild and moderate renal impairment, respectively. In contrast, it was higher by 28% and 9% in patients with severe renal dysfunction and end-stage renal disease on dialysis treatment, respectively. Only 5.4% of the&#x000a0;deucravacitinib dosage was&#x000a0;removed from the circulation&#x000a0;during&#x000a0;dialysis procedures.</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No adjustments are recommended in patients with concomitant mild (Child-Pugh A) or moderate (Child-Pugh B) liver impairment. Deucravacitinib is not recommended&#x000a0;for patients with severe hepatic dysfunction (Child-Pugh C).<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;Compared to&#x000a0;patients with normal liver function, the Cmax of deucravacitinib was 4%, 10%, and 1% higher in&#x000a0;patients with mild, moderate, and severe hepatic impairment, respectively. For similar patient groups, the area under the curve to infinity (AUC<sub>inf</sub>) was 10%, 40%, and 43% higher. Compared to patients with normal liver function, the Cmax of BMT-153261 was 25%, 59%, and 79% lower in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B),&#x000a0;and severe (Child-Pugh Class C) hepatic dysfunction, respectively. For similar patient groups, the AUC<sub>inf</sub>&#x000a0;was 3%, 20%, and 50% lower.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;The data available from the case studies on deucravacitinib use during pregnancy are not adequate to assess the drug-associated risk of major congenital malformations, loss of pregnancy (abortion), and unfavorable fetal and maternal outcomes.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;In preclinical studies, no adverse effects were observed on the development of embryo and fetus with oral administration of deucravacitinib to animals such as rats and rabbits during the phase of organogenesis at doses that were 91 times higher than the maximum recommended human dosage (MRHD) of 6 mg once a day. If the patient conceives while on deucravacitinib, pregnancy is reported at the adverse event reporting line of the drug manufacturing company.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Data on the secretion of deucravacitinib in human milk, its effects on lactogenesis, and its effects on breastfed infants are not available. During animal studies, deucravacitinib was found in the milk of rats. While prescribing deucravacitinib, the health benefits of breastfeeding infants and the clinical need for therapy must be weighed against the potential adverse effects on the breastfed child.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and effectiveness of deucravacitinib have not been established in the pediatric patient population.</p>
        <p><bold>Older patients:</bold>&#x000a0;In&#x000a0;one clinical trial, 1519 patients with plaque psoriasis received deucravacitinib therapy. Of these, 152 patients (10%) were 65 or older, and 21 patients (1.4%) were 75. During the first 16 weeks of observation, severe adverse reactions occurred in&#x000a0;80 patients older than 65 and&#x000a0;12 patients&#x000a0;older than 75; these patients were administered deucravacitinib without switching treatment arms. This rate of severe reactions was determined to be significantly higher than in younger patients. These severe effects included infection and many required treatment discontinuation. No&#x000a0;significant&#x000a0;difference in efficacy was observed between&#x000a0;older and younger adults.</p>
      </sec>
      <sec id="article-152980.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Deucravacitinib has consistently demonstrated a safety profile.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;The safety of deucravacitinib was assessed in&#x000a0;2 placebo-controlled and active-controlled (PSO-1 and PSO-2) clinical trials and an open-label-extension (OLE) trial in which&#x000a0;patients could enroll after completing the PSO-1 or PSO-2 trials.&#x000a0;A total of 1519&#x000a0;patients&#x000a0;with moderate-to-severe plaque psoriasis received&#x000a0;deucravacitinib 6 mg once daily. Of these, 1141&#x000a0;patients&#x000a0;were exposed to deucravacitinib for at least 12 months.</p>
        <p>At week 16 in the PSO-1 trial, significantly higher response rates were observed&#x000a0;in patients receiving deucravacitinib&#x000a0;compared to placebo or apremilast. Therapeutic efficacy improved with treatment longer than 16 weeks and was maintained through week 52. At week 16 in the PSO-2 trial, more than 50% of patients receiving deucravacitinib achieved superior clearing compared to apremilast. Across multiple efficacy endpoints, deucravacitinib consistently demonstrated superiority to apremilast and was well tolerated in patients with moderate-to-severe plaque psoriasis.<xref ref-type="bibr" rid="article-152980.r25">[25]</xref>&#x000a0;A large proportion of&#x000a0;patients treated with deucravacitinib reported a Psoriasis Symptoms and Signs Diary (PSSD) symptoms score of 0 at week 16, indicating relief from itching, pain, stinging, burning, and skin tightness (8% in deucravacitinib group versus 1% in the placebo arm) in both clinical trials.<xref ref-type="bibr" rid="article-152980.r26">[26]</xref></p>
        <p>The exposure-adjusted incidence rate for adverse events in&#x000a0;patients who were treated with deucravacitinib from through week 52 without interchanging treatment arm did not increase in comparison with the rate reported during the first 16 weeks of therapy.</p>
        <p>Most of the adverse reactions were mild in severity.&#x000a0;Respiratory&#x000a0;complications&#x000a0;were&#x000a0;the most common adverse events:</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infections</p>
          </list-item>
          <list-item>
            <p>Nasopharyngitis</p>
          </list-item>
          <list-item>
            <p>Pharyngitis</p>
          </list-item>
          <list-item>
            <p>Sinusitis</p>
          </list-item>
          <list-item>
            <p>Rhinitis</p>
          </list-item>
          <list-item>
            <p>Rhinotracheitis</p>
          </list-item>
          <list-item>
            <p>Tracheitis</p>
          </list-item>
          <list-item>
            <p>Laryngitis</p>
          </list-item>
          <list-item>
            <p>Tonsillitis</p>
          </list-item>
        </list>
        <p>Other adverse reactions&#x000a0;included oral ulcers, stomatitis, and acne.<xref ref-type="bibr" rid="article-152980.r14">[14]</xref><xref ref-type="bibr" rid="article-152980.r27">[27]</xref>&#x000a0;Herpes simplex occurred in less than 1% of&#x000a0;patients&#x000a0;in the deucravacitinib group.</p>
        <p>Severe adverse reactions in patients treated with deucravacitinib included:</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory infections</p>
          </list-item>
          <list-item>
            <p>Creatine phosphokinase&#x000a0;elevations</p>
          </list-item>
          <list-item>
            <p>Herpes simplex</p>
          </list-item>
          <list-item>
            <p>Mouth ulcers</p>
          </list-item>
          <list-item>
            <p>Folliculitis</p>
          </list-item>
          <list-item>
            <p>Acne</p>
          </list-item>
        </list>
        <p>The rate of severe adverse reactions&#x000a0;necessitating discontinuation of therapy in&#x000a0;patients who were treated with deucravacitinib was 2.4%, in comparison with 3.8% for the placebo group.<xref ref-type="bibr" rid="article-152980.r28">[28]</xref></p>
        <p><bold>Infection:</bold>&#x000a0;Deucravacitinib may increase the risk of infections. In the placebo-controlled 16-week period, infections were reported in 29% of the&#x000a0;patients treated with deucravacitinib (116 events per 100 person-years) compared with 22% treated with the placebo (83.7 events per 100 person-years). Most infections were not serious, were in the mild to moderate severity category, and did not cause discontinuation of deucravacitinib therapy. During this same period, serious infections occurred in 5&#x000a0;patients (2.0 per 100 patient-years) in the deucravacitinib group and 2&#x000a0;patients (1.6 per 100&#x000a0;patient-years) in the placebo group. During the 52-week treatment period, pneumonia and COVID-19 were the most common serious infections reported.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref></p>
        <p><bold>Malignancy:</bold>&#x000a0;During the 52-week treatment phase of the PSO-1 and PSO-2 clinical trials with a total exposure of 986 patient-years to deucravacitinib, malignancies were observed in 3&#x000a0;patients&#x000a0;who received deucravacitinib therapy (0.3 per 100&#x000a0;patient-years), including a case of breast cancer, hepatocellular carcinoma, and lymphoma after treatment for 24, 32, and 25 weeks, respectively.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;During PSO-1, PSO-2, and the open-label extension (OLE) trials, 3&#x000a0;patients (0.1 per 100 patient-years) in total developed lymphoma after 25, 77, and 98 weeks of treatment with deucravacitinib.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Various studies have failed to demonstrate any clinically&#x000a0;significant differences in the pharmacokinetics of deucravacitinib when co-administered with the following drugs:<xref ref-type="bibr" rid="article-152980.r3">[3]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Fluvoxamine (CYP1A2 inhibitor)</p>
          </list-item>
          <list-item>
            <p>Ritonavir (CYP1A2 inducer)</p>
          </list-item>
          <list-item>
            <p>Famotidine (H2 receptor antagonist)</p>
          </list-item>
          <list-item>
            <p>Rabeprazole (proton pump inhibitor)</p>
          </list-item>
          <list-item>
            <p>Cyclosporine (dual Pgp/BCRP inhibitor)</p>
          </list-item>
          <list-item>
            <p>Pyrimethamine (OCT1 inhibitor)</p>
          </list-item>
          <list-item>
            <p>Diflunisal (UGT 1A9 inhibitor)</p>
          </list-item>
        </list>
        <p>Similarly,&#x000a0;studies have&#x000a0;failed to demonstrate&#x000a0;any clinically significant differences in the pharmacokinetics of the drugs listed below when administered concomitantly with deucravacitinib:</p>
        <list list-type="bullet">
          <list-item>
            <p>Norethindrone acetate and ethinyl estradiol (oral contraceptives)</p>
          </list-item>
          <list-item>
            <p>Rosuvastatin</p>
          </list-item>
          <list-item>
            <p>Methotrexate</p>
          </list-item>
          <list-item>
            <p>Mycophenolate mofetil (MMF)</p>
          </list-item>
        </list>
        <p><bold>Cytochrome P450 (CYP) enzymes:</bold><italic toggle="yes">&#x000a0;</italic>Deucravacitinib is not an inducer of CYP1(A2), CYP2(B6), or CYP3(A4) group of enzymes. Deucravacitinib is not an inhibitor of enzymes CYP1(A2), CYP2(B6), CYP2(C8), CYP2(C9), CYP2(C19), CYP2(D6), or CYP3(A4).</p>
        <p><bold>Carboxylesterase&#x000a0;(CES) enzymes:</bold>&#x000a0;Deucravacitinib is not a class CES(2) enzyme suppressor.</p>
        <p><bold>Uridine diphosphate (UDP)-glucuronosyltransferase (UGT) enzymes:</bold><italic toggle="yes">&#x000a0;</italic>Deucravacitinib is not a suppressor of enzymes UGT1(A1), UGT1(A4), UGT1(A6), UGT1(A9), or UGT2(B7).</p>
        <p><bold>Transporter enzymes:</bold><italic toggle="yes">&#x000a0;</italic>Deucravacitinib is a substrate of BCRP, OCT1, and Pgp, but not MATE1, MATE2K, NTCP, OAT1, OAT3, OATP, or OCT2. deucravacitinib is a suppressor of BCRP and OATP1B3 but deucravacitinib is not an inhibitor of BSEP, MATE1, MATE2-K, MRP2, NTCP, OATP1B1, OAT1, OAT3, OCT1, OCT2, or Pgp.</p>
      </sec>
      <sec id="article-152980.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Deucravacitinib is contraindicated for any patient with a history of hypersensitivity to deucravacitinib or any excipients used in the formula. Deucravacitinib&#x000a0;administration&#x000a0;in combination with other potent immunosuppressants is not recommended.<xref ref-type="bibr" rid="article-152980.r1">[1]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Hypersensitivity:</bold> Hypersensitivity reactions have been observed in&#x000a0;patients on deucravacitinib therapy. If a clinically significant hypersensitivity reaction such as angioedema occurs, the appropriate treatment should be administered, and&#x000a0;deucravacitinib should be permanently discontinued.&#x000a0;</p>
        <p><bold>Infections:</bold> Patients on deucravacitinib therapy are susceptible to infections and reactivation infections.<xref ref-type="bibr" rid="article-152980.r24">[24]</xref>&#x000a0;Respiratory tract infections and herpes simplex are the most common.&#x000a0;Severe infections include pneumonia and COVID-19. Therefore, deucravacitinib is not recommended for patients with&#x000a0;life-threatening&#x000a0;or active infections, including a medical history of exposure to tuberculosis, a history of a severe or opportunistic infection, and underlying conditions that may predispose them to infections.</p>
        <p>During and after deucravacitinib treatment, close patient monitoring for signs and symptoms of infection is required. If an infection develops, appropriate antimicrobial therapy is initiated, and the patient is closely monitored. Deucravacitinib therapy is&#x000a0;suspended if the patient develops a dangerous infection, and the treatment can be resumed after the infection has resolved.</p>
        <p><bold>Viral reactivation:</bold>&#x000a0;Clinical trials reported reactivation of latent herpes virus leading to herpes zoster and herpes simplex. In the 16-week-long placebo-controlled phase, herpes simplex infection was reported by 17 patients (6.8 per 100 patient-years) who were on deucravacitinib treatment and 1 patient (0.8 per 100 patient-years) who received a placebo.</p>
        <p>A severe type of herpes infection affecting multiple dermatomes was reported in immunocompetent&#x000a0;patients who were on deucravacitinib therapy. During PSO-1, PSO-2, and the open-label extension (OLE) trial, most of the&#x000a0;patients who reported herpes zoster events while receiving deucravacitinib were&#x000a0;younger than age 50.</p>
        <p>The effect of deucravacitinib on the reactivation of chronic viral hepatitis is unknown. During screening,&#x000a0;patients&#x000a0;who tested positive for hepatitis B or C were not included in clinical trials. According to clinical guidelines, viral hepatitis should be screened and monitored for reactivation infection before initiating therapy and during treatment with deucravacitinib.<xref ref-type="bibr" rid="article-152980.r24">[24]</xref>&#x000a0;If signs of reactivation occur, consultation with a hepatitis specialist should be&#x000a0;arranged. Deucravacitinib is not recommended for patients&#x000a0;with&#x000a0;active hepatitis B or C.</p>
        <p><bold>Tuberculosis:</bold>&#x000a0;Deucravacitinib is a systemic therapy that inhibits tyrosine kinase 2, a member of the Jak family.&#x000a0;Before initiating therapy with deucravacitinib, patients must be evaluated for latent and active tuberculosis (TB).<xref ref-type="bibr" rid="article-152980.r24">[24]</xref>&#x000a0;A blood-based&#x000a0;interferon-gamma release assay (IGRA) can detect mycobacterium tuberculosis infection.</p>
        <p>Deucravacitinib is contraindicated in patients with active TB. Starting therapy for latent TB before administering deucravacitinib is recommended. If the patient has a medical history of TB, latent or active, and an adequate course of therapy cannot be confirmed, initiating anti-TB treatment before administering deucravacitinib may be considered. Patients on deucravacitinib treatment should be monitored for signs and symptoms of active TB during and after treatment.</p>
        <p><bold>Malignancy:&#x000a0;</bold>Various malignancies, including lymphomas, were reported in&#x000a0;patients enrolled in clinical trials with deucravacitinib.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;Clinicians should&#x000a0;weigh the benefits versus risks for the patient before initiating or continuing treatment, particularly in patients with a known malignancy (other than&#x000a0;resolved non-melanomatous dermatological cancers) and patients who develop a malignancy while receiving&#x000a0;deucravacitinib therapy.</p>
        <p><bold>Rhabdomyolysis:&#x000a0;</bold>Cases of rhabdomyolysis&#x000a0;have been&#x000a0;reported in&#x000a0;patients&#x000a0;receiving deucravacitinib, which resulted in therapy interruption or permanent discontinuation. Deucravacitinib was associated with a higher incidence of asymptomatic elevation in levels of creatine phosphokinase (CPK) and rhabdomyolysis compared to treatment with a placebo.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;The discontinuation of deucravacitinib is needed if marked elevation in CPK levels occurs or myopathy is suspected or diagnosed. Patients should promptly report any unexplained symptoms, such as muscle aches, tenderness, weakness, malaise, or fever.</p>
        <p><bold>Immunizations:&#x000a0;</bold>Before starting deucravacitinib therapy, all age-appropriate immunizations, including&#x000a0;the herpes zoster vaccination,&#x000a0;should be completed.&#x000a0;The immune response to live or killed vaccines has not been established.&#x000a0;Patients receiving deucravacitinib treatment should avoid live vaccines.</p>
        <p><bold>Jak inhibition:</bold> The&#x000a0;involvement of Tyk2 in adverse reactions associated with Jak inhibitor therapy has not been well established.<bold>&#x000a0;</bold>One randomized post-marketing safety trial&#x000a0;studied the effect of a Jak inhibitor in patients with rheumatoid arthritis (RA). Along with at least one cardiovascular risk factor, higher rates of all-cause mortality were observed in patients aged 50 and older who received Jak inhibitor treatment compared to&#x000a0;TNF blockers. All-cause mortality included sudden cardiovascular death, major cardiovascular adverse events, deep venous thrombosis, pulmonary embolism, overall thrombosis, and malignancies (excluding non-melanomatous dermatological cancers).</p>
      </sec>
      <sec id="article-152980.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients on deucravacitinib require follow-up visits to evaluate their response to therapy. Close monitoring of the patients for prompt detection and effective management of adverse drug reactions such as infections, rhabdomyolysis, hepatic dysfunction, and hypertriglyceridemia is required.<xref ref-type="bibr" rid="article-152980.r24">[24]</xref> In addition, patients are assessed for complications associated with psoriasis. At a dosage range up to 6 times the recommended daily dosage of 6 mg, deucravacitinib does not cause any clinically significant prolongation of QTc interval.<xref ref-type="bibr" rid="article-152980.r29">[29]</xref></p>
        <p>Patients receiving deucravacitinib therapy should be monitored using the following markers:</p>
        <list list-type="bullet">
          <list-item>
            <p>Triglycerides</p>
          </list-item>
          <list-item>
            <p>Lipids</p>
          </list-item>
          <list-item>
            <p>Liver enzymes</p>
          </list-item>
          <list-item>
            <p>Creatine phosphokinase</p>
          </list-item>
          <list-item>
            <p>Glomerular filtration rate</p>
          </list-item>
        </list>
        <p><bold>Triglycerides:</bold> Therapy with deucravacitinib&#x000a0;is associated with increased&#x000a0;triglyceride levels.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;However, the effect of a rise in this parameter on morbidity and mortality due to cardiovascular conditions has been undetermined. When on deucravacitinib treatment, the serum triglyceride levels need to be evaluated periodically per the clinical guidelines for hyperlipidemia. The clinical management of patients with hyperlipidemia is done according to the management guidelines for hyperlipidemia.</p>
        <p><bold>Lipids:</bold>&#x000a0;The increase in mean triglycerides level by 10.3 mg/dL was observed in the&#x000a0;patients treated with deucravacitinib during the 16-week treatment period, and the reported increase was by 9.1 mg/dL during the 52-week treatment period.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref></p>
        <p><bold>Liver enzymes:</bold>&#x000a0;Deucravacitinib is associated with elevated serum aminotransferase&#x000a0;levels, but no clinically apparent acute hepatic injury cases&#x000a0;have been&#x000a0;reported.<xref ref-type="bibr" rid="article-152980.r30">[30]</xref>&#x000a0;Per the routine protocol, liver&#x000a0;enzymes&#x000a0;should be evaluated at baseline and periodically in patients with known or suspected hepatic disorders. If hepatic enzymes increase while on deucravacitinib, and drug-induced hepatic injury is suspected, interruption of deucravacitinib therapy is necessary until the diagnosis of hepatocellular injury is excluded.</p>
        <p><bold>Creatine phosphokinase:</bold>&#x000a0;In the placebo-controlled period of 16 weeks,&#x000a0;elevated creatine phosphokinase (CPK) levels, including Grade 4 severity, were observed in 23&#x000a0;patients (9.3 per 100 patient-years) receiving deucravacitinib therapy and 5&#x000a0;patients (4.1 per 100 patient-years) who were on placebo treatment.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref></p>
        <p><bold>Glomerular filtration rate:</bold>&#x000a0;During the placebo-controlled 16-week period,&#x000a0;for&#x000a0;patients with moderate impairment of renal function (eGFR 30 to 59 mL/min) at baseline, reduction in GFR reductions were observed in 4&#x000a0;patients (1.6 per 100&#x000a0;patient-years) who were on deucravacitinib treatment, and 1&#x000a0;patient (0.8 per 100 patient-years) on placebo therapy. Two of the&#x000a0;patients treated with deucravacitinib had worsening baseline proteinuria.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref></p>
      </sec>
      <sec id="article-152980.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Recommendations</bold>
</p>
        <p>No clinical data is available for experience with deucravacitinib overdosage. If overdosage occurs in any patients, it is recommended to contact the Poison Help line for additional management of the condition according to the drug overdosage protocol. The elimination of deucravacitinib by treatment with hemodialysis was small in extent, up to 5.4% of the dosage per dialysis therapy, and therefore, limiting the use of hemodialysis in the treatment of overdosage or intoxication with deucravacitinib.&#x000a0;</p>
        <p>Various studies using rate models have demonstrated no&#x000a0;carcinogenicity was observed in male or female rats that administered deucravacitinib orally at doses up to 15 mg/kg/day, which is 51-fold higher than the MRHD as per AUC comparison.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;In rats of the female gender, deucravacitinib had no effects on parameters of reproduction such as mating, fertility, or early development of the embryo at orally administered doses up to 50 mg/kg/day which is 171-fold higher than the MRHD, according to the comparison of AUC. In the male rat, deucravacitinib had no effects on mating, sperm morphology, fertility, or early embryonic parameters of their offspring at orally administered doses up to 50 mg/kg/day, which is 224 times higher than the MRHD according to a comparison of AUC.</p>
      </sec>
      <sec id="article-152980.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Psoriasis is a chronic, immune-mediated inflammatory disorder. The disease burden is equally distributed in both genders worldwide. This condition causes physical disfigurement, which has a profound psychosocial impact, leading to low self-esteem, stigmatization, and isolation. Additionally, it reduces the lifespan of patients due to associated comorbidities. The expensive and prolonged treatment imposes a substantial economic burden on the patient and healthcare system. The community needs safer and more effective treatment to address these issues. Deucravacitinib is a breakthrough in the targeted treatment of moderate-to-severe plaque psoriasis.<xref ref-type="bibr" rid="article-152980.r3">[3]</xref>&#x000a0;The interdisciplinary healthcare team&#x000a0;must work together to ensure the therapeutic safety and efficacy of deucravacitinib.</p>
        <p>Clinicians prescribe deucravacitinib to the appropriate patients when they verbally consent to the treatment plan, set realistic treatment goals, and provide information about the potential adverse events of the drug therapy. An initial consultation is an excellent opportunity to develop a positive rapport with the patients, promoting a healthy mindset and mental well-being. The specialists can enhance the care of patients by offering invaluable input and leveraging their expertise.</p>
        <p>Pharmacists can verify the drug dosing and perform a drug interaction check. They can also provide information on drug storage at home. The pharmacist can recommend reading an FDA-approved patient "Medication Guide" before starting deucravacitinib therapy each time the prescription is renewed.</p>
        <p>Nurses can educate patients on the proper administration of drugs. They can also monitor adverse reactions, perform preliminary assessments of therapeutic effectiveness during follow-up visits, and verify the patient's compliance with the pharmacotherapy.</p>
        <p>Nurses and pharmacists must communicate openly with prescribing physicians to report or discuss any concerns related to deucravacitinib therapy or the patient's other drug regimen. Such collaborative, interdisciplinary healthcare team communication is necessary to optimize patient care.</p>
        <p>The patients are counseled to immediately seek professional assistance upon experiencing adverse reactions. Patients with plaque psoriasis often experience major depression with a sense of lost control over their medical condition and routine lives. The interprofessional healthcare team plays a crucial role in empowering the patients by promoting a perception of control and demonstrating comprehensive and collaborative efforts. This approach&#x000a0;facilitates positive healthcare outcomes in the patients receiving deucravacitinib therapy.</p>
      </sec>
      <sec id="article-152980.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=152980&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=152980">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/152980/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=152980">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-152980.s10">
        <title>References</title>
        <ref id="article-152980.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>417</fpage>
            <page-range>417-435</page-range>
            <pub-id pub-id-type="pmid">36592300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chimalakonda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Catlett</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tagen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Throup</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>1763</fpage>
            <page-range>1763-1776</page-range>
            <pub-id pub-id-type="pmid">34471993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>82</volume>
            <issue>17</issue>
            <fpage>1671</fpage>
            <page-range>1671-1679</page-range>
            <pub-id pub-id-type="pmid">36401743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Truong</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Singal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taranto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>416</fpage>
            <page-range>416-427</page-range>
            <pub-id pub-id-type="pmid">37341177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rusi&#x000f1;ol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Feb</month>
            <day>08</day>
            <volume>24</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">36834806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000e9;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.</article-title>
            <source>Drugs Context</source>
            <year>2023</year>
            <volume>12</volume>
            <pub-id pub-id-type="pmid">37168876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catlett</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.</article-title>
            <source>Clin Transl Sci</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-164</page-range>
            <pub-id pub-id-type="pmid">36325947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mease</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Behrens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kivitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>81</volume>
            <issue>6</issue>
            <fpage>815</fpage>
            <page-range>815-822</page-range>
            <pub-id pub-id-type="pmid">35241426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blauvelt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sofen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Merola</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hippeli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colston</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Balagula</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tha&#x000e7;i</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>775</fpage>
            <page-range>775-782</page-range>
            <pub-id pub-id-type="pmid">38122848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moussa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stanciu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Netchiporouk</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report.</article-title>
            <source>SAGE Open Med Case Rep</source>
            <year>2023</year>
            <volume>11</volume>
            <fpage>2050313X231213135</fpage>
            <pub-id pub-id-type="pmid">38033914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Grover</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iorizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Piraccini</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rigopoulos</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lipner</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Nail psoriasis and nail lichen planus: Updates on diagnosis and management.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>585</fpage>
            <page-range>585-596</page-range>
            <pub-id pub-id-type="pmid">38007038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingston</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blauvelt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.</article-title>
            <source>J Psoriasis Psoriatic Arthritis</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>156</fpage>
            <page-range>156-165</page-range>
            <pub-id pub-id-type="pmid">38188537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Oral Psoriasis Therapies.</article-title>
            <source>Dermatol Clin</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-363</page-range>
            <pub-id pub-id-type="pmid">38796267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pike</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Hobar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sharkey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wegman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Catlett</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>242</fpage>
            <page-range>242-252</page-range>
            <pub-id pub-id-type="pmid">36369798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ezeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vleugels</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Shahriari</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Discoid lupus erythematosus successfully treated with deucravacitinib.</article-title>
            <source>JAAD Case Rep</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>49</volume>
            <fpage>59</fpage>
            <page-range>59-61</page-range>
            <pub-id pub-id-type="pmid">38883165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roskoski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.</article-title>
            <source>Pharmacol Res</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>200</volume>
            <fpage>107059</fpage>
            <pub-id pub-id-type="pmid">38216005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolte</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Mesas-Fern&#x000e1;ndez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Dommisch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghoreschi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Solimani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus.</article-title>
            <source>Exp Dermatol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>e15080</fpage>
            <pub-id pub-id-type="pmid">38628035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merola</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>TYK2: an emerging therapeutic target in rheumatic disease.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>232</fpage>
            <page-range>232-240</page-range>
            <pub-id pub-id-type="pmid">38467779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roskoski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.</article-title>
            <source>Pharmacol Res</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>189</volume>
            <fpage>106642</fpage>
            <pub-id pub-id-type="pmid">36754102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishtiaque</surname>
                <given-names>GMA</given-names>
              </name>
              <name>
                <surname>Supti</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Emran</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>A paradigm shift in psoriasis treatment: deucravacitinib's significance.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>85</volume>
            <issue>12</issue>
            <fpage>5866</fpage>
            <page-range>5866-5868</page-range>
            <pub-id pub-id-type="pmid">38098574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Reactive oxygen species-responsive supramolecular deucravacitinib self-assembly polymer micelles alleviate psoriatic skin inflammation by reducing mitochondrial oxidative stress.</article-title>
            <source>Front Immunol</source>
            <year>2024</year>
            <volume>15</volume>
            <fpage>1407782</fpage>
            <pub-id pub-id-type="pmid">38799436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chimalakonda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Marchisin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>956</fpage>
            <page-range>956-965</page-range>
            <pub-id pub-id-type="pmid">37587797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dockens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marchisin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Chimalakonda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and Safety of the Tyrosine Kinase&#x000a0;2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>3153</fpage>
            <page-range>3153-3164</page-range>
            <pub-id pub-id-type="pmid">37981596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potestio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ruggiero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabbrocini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martora</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Megna</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature.</article-title>
            <source>Psoriasis (Auckl)</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>19</fpage>
            <page-range>19-26</page-range>
            <pub-id pub-id-type="pmid">37168605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Gooderham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tha&#x000e7;i</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Imafuku</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colston</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Throup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Linaberry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blauvelt</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-39</page-range>
            <pub-id pub-id-type="pmid">35820547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000e9;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib for the Treatment of Psoriatic Disease.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>813</fpage>
            <page-range>813-822</page-range>
            <pub-id pub-id-type="pmid">35960487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imafuku</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohtsuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colston</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Napoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.</article-title>
            <source>J Dermatol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>365</fpage>
            <page-range>365-379</page-range>
            <pub-id pub-id-type="pmid">38268101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tha&#x000e7;i</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sofen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kircik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bagel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colston</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Throup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sekaran</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Linaberry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr&#x000a0;Evaluation of&#x000a0;TYK2 inhibitor psoriasis second trial.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-51</page-range>
            <pub-id pub-id-type="pmid">36115523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chimalakonda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Darbenzio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dockens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marchisin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Throup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>442</fpage>
            <page-range>442-453</page-range>
            <pub-id pub-id-type="pmid">35182043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-152980.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <chapter-title>Deucravacitinib</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">38471025</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
